Interview with Matthew Shissler, CEO of Cord Blood America, Inc.
This interview has expired.
Click here to find stocks, with exciting stories, and management committed to maximizing shareholder value.
Special deals for our readers
Are you qualified for the Visa Black Card?
The World’s Most Prestigious and Versatile Credit Card. Apply Now!
Be a more profitable investor:
What’s Jim Cramer trading in his personal portfolio? Click here
Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing.
Find out why TradeKing.com was ranked #1 Discount Broker by SmartMoney Magazine two years running! (August 2006 & 2007).
LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount.
Click here to get access to powerful investing tools only available at Investor’s Business Daily.
Cord Blood America, Inc. (OTC BB: CBAI) is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for use in stem cell therapy. It is a holding company whose subsidiaries include Cord Partners, Inc. (Cord), CorCell Co. Inc., CorCell Ltd., CBA Professional Services, Inc., doing business as BodyCells, Inc. (BodyCells), CBA Properties, Inc. (Properties), and Career Channel Inc, doing business as Rainmakers International (Rain). On February 28, 2007, the Company acquired CorCell, Inc. On August 1, 2007, it entered into an agreement with Progenitor Cell Therapy, LLC (PCT) for testing, processing and storage of cord blood samples. As a result of the agreement with PCT, the Company terminated its agreement with Bergen Community Regional Blood Center. On August 20, 2007, CBAI acquired specific assets from CureSource, Inc.